Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · Real-Time Price · USD
48.56
+1.48 (3.14%)
Jun 9, 2026, 4:00 PM EDT - Market closed

Travere Therapeutics Stock Forecast

Stock Price Forecast

According to 15 analysts polled by S&P Global, Travere Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $55.07. The average 1-year stock price forecast is 13.41% higher than the current stock price, while the lowest is $43 (-11.45%) and the highest is $67 (+37.97%).

Price Target: $55.07 (+13.41%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$43$55.07$55$67
Change-11.45%+13.41%+13.26%+37.97%

Analyst Ratings

The average analyst rating for Travere Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingJan '26Feb '26Mar '26Apr '26May '26Jun '26
Strong Buy121212121212
Buy111222
Hold222111
Sell000000
Strong Sell000000
Total151515151515

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
H.C. Wainwright
H.C. Wainwright
Buy
Reiterates
$67
BuyReiterates$67+37.97%Jun 5, 2026
Citi
Citi
Buy
Reiterates
$59$62
BuyReiterates$59$62+27.68%Jun 3, 2026
Canaccord Genuity
Canaccord Genuity
Buy
Maintains
$56
BuyMaintains$56+15.32%Jun 3, 2026
Piper Sandler
Piper Sandler
Buy
Maintains
$49
BuyMaintains$49+0.91%Jun 3, 2026
Wedbush
Wedbush
Buy
Maintains
$55
BuyMaintains$55+13.26%Jun 3, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
699.54M
from 490.73M
Increased by 42.55%
Revenue Next Year
969.50M
from 699.54M
Increased by 38.59%
EPS This Year
1.63
from 0.91
Increased by 79.34%
EPS Next Year
4.93
from 1.63
Increased by 201.95%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
131.84M109.46M145.24M233.18M490.73M699.54M
Revenue Growth
-33.52%-16.97%32.69%60.55%110.46%42.55%
Gross Profit
-73.14M-122.29M-111.20M7.94M274.38M686.77M
Gross Margin
-55.48%-111.72%-76.57%3.40%55.91%98.18%
Operating Income
-199.43M-319.81M-376.74M-256.18M-62.82M-38.34M
Net Income
-180.09M-278.48M-111.40M-321.55M-25.55M27.64M
EPS
----0.911.63
EPS Growth
-----79.34%
Forward PE
----38.0829.75
Free Cash Flow
-60.79M-163.35M-178.11M-228.53M-38.30M-8.00M
No. Analysts
-----14
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High941.1M
Avg699.5M
Low595.0M

Revenue Growth

Revenue Growth202620272028
High
91.8%
Avg
42.6%
Low
21.2%

EPS Forecast

EPS202620272028
High2.80
Avg1.63
Low0.22

EPS Growth

EPS Growth202620272028
High
207.7%
Avg
79.3%
Low
-76.2%